Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313389063> ?p ?o ?g. }
- W4313389063 endingPage "112" @default.
- W4313389063 startingPage "112" @default.
- W4313389063 abstract "Ovarian cancers rank first in both aggressiveness and dismal prognosis among gynecological neoplasms. The poor outcome is explained by the fact that most patients present with late-stage disease and progress through the first line of treatment. Ovarian neoplasms, especially epithelial ovarian cancers, are diagnosed at advanced/metastatic stages, often with a high angiogenesis index, one of the hallmarks of ovarian cancers with rapid progression and poor outcome as resistance to anti-angiogenic therapy develops. Despite therapy, the metastatic progression of aggressive ovarian cancer is a spectacularly selective function of tumor cells aided and abetted by the immune, mesenchymal and angiogenic components of the tumor microenvironment (TME) that enforces several pro-metastatic event(s) via direct and indirect interactions with stromal immune cells, cancer-associated fibroblasts (CAFs), and vascular endothelial cells. Since transdifferentiation of tumor endothelium is one of the major sources of CAFs, we hypothesized that ovarian CAF plays a critical role in resisting anti-angiogenic effects via direct crosstalk with endothelium and hence plays a direct role in the development of resistance to anti-angiogenic drugs. To test the hypothesis, we set up a hybrid ex vivo model for co-culture comprising Patient-Derived ex vivo primary CAFs from ovarian tumor samples and human umbilical vein endothelial cells (HUVEC). Patient-Derived CAFs were characterized by the mRNA and protein expression of positive (SMA, S100A4, TE-7, FAP-A, CD90/THY1), negative (EpCAM, CK 8,18, CD31, CD44, CD45), functional (PDGFRA, TGFB1, TGFB2, TGFRA) and immunological markers (PD-L1, PD-L2, PD-1) associated with CAFs by qRT-PCR, flow cytometry, Western blot, and ICC. Data from our HUVEC-on-CAF ex vivo Hybrid Co-Culture (HyCC) study demonstrate the pro-angiogenic effect of Patient-Derived ovarian CAFs by virtue of their ability to resist the effect of anti-angiogenic drugs, thereby aiding the development of resistance to anti-angiogenic drugs. Ascertaining direct experimental proof of the role of CAFs in developing resistance to specific anti-angiogenic drugs will provide an opportunity to investigate new drugs for counteracting CAF resistance and normalizing/re-educating TME in aggressive ovarian cancers. Our data provide a unique experimental tool for the personalized testing of anti-angiogenic drugs, positively predicting the development of future resistance to anti-angiogenic drugs well before it is clinically encountered in patients." @default.
- W4313389063 created "2023-01-06" @default.
- W4313389063 creator A5001657519 @default.
- W4313389063 creator A5007390110 @default.
- W4313389063 creator A5012509754 @default.
- W4313389063 creator A5020829125 @default.
- W4313389063 creator A5029357432 @default.
- W4313389063 creator A5030281378 @default.
- W4313389063 creator A5031027334 @default.
- W4313389063 creator A5035051897 @default.
- W4313389063 creator A5067979561 @default.
- W4313389063 creator A5070455668 @default.
- W4313389063 date "2023-01-01" @default.
- W4313389063 modified "2023-09-26" @default.
- W4313389063 title "Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers" @default.
- W4313389063 cites W1224756471 @default.
- W4313389063 cites W1972905381 @default.
- W4313389063 cites W1978099625 @default.
- W4313389063 cites W1979761609 @default.
- W4313389063 cites W1983575915 @default.
- W4313389063 cites W1988224215 @default.
- W4313389063 cites W1997508706 @default.
- W4313389063 cites W2017176305 @default.
- W4313389063 cites W2027403533 @default.
- W4313389063 cites W2045648996 @default.
- W4313389063 cites W2062809449 @default.
- W4313389063 cites W2063249586 @default.
- W4313389063 cites W2064726235 @default.
- W4313389063 cites W2079905347 @default.
- W4313389063 cites W2098757775 @default.
- W4313389063 cites W2101037339 @default.
- W4313389063 cites W2103928688 @default.
- W4313389063 cites W2107498524 @default.
- W4313389063 cites W2110088809 @default.
- W4313389063 cites W2112475965 @default.
- W4313389063 cites W2135947389 @default.
- W4313389063 cites W2146878122 @default.
- W4313389063 cites W2170928115 @default.
- W4313389063 cites W2171658624 @default.
- W4313389063 cites W2205800959 @default.
- W4313389063 cites W2404284395 @default.
- W4313389063 cites W2411330078 @default.
- W4313389063 cites W2591299408 @default.
- W4313389063 cites W2649656222 @default.
- W4313389063 cites W2730217323 @default.
- W4313389063 cites W2757105214 @default.
- W4313389063 cites W2762514399 @default.
- W4313389063 cites W2767841352 @default.
- W4313389063 cites W2774854449 @default.
- W4313389063 cites W2802782143 @default.
- W4313389063 cites W2888530993 @default.
- W4313389063 cites W2888932782 @default.
- W4313389063 cites W2895852536 @default.
- W4313389063 cites W2896737957 @default.
- W4313389063 cites W2897581545 @default.
- W4313389063 cites W2899414628 @default.
- W4313389063 cites W2914714363 @default.
- W4313389063 cites W2953413611 @default.
- W4313389063 cites W2961804006 @default.
- W4313389063 cites W2966786527 @default.
- W4313389063 cites W2972235392 @default.
- W4313389063 cites W2982701446 @default.
- W4313389063 cites W2990255708 @default.
- W4313389063 cites W2992107509 @default.
- W4313389063 cites W3012023346 @default.
- W4313389063 cites W3013496918 @default.
- W4313389063 cites W3023274953 @default.
- W4313389063 cites W3023906975 @default.
- W4313389063 cites W3033759475 @default.
- W4313389063 cites W3036895040 @default.
- W4313389063 cites W3038084551 @default.
- W4313389063 cites W3042047307 @default.
- W4313389063 cites W3080225990 @default.
- W4313389063 cites W3080263585 @default.
- W4313389063 cites W3080645356 @default.
- W4313389063 cites W3096536399 @default.
- W4313389063 cites W3109819734 @default.
- W4313389063 cites W3110352255 @default.
- W4313389063 cites W3129141641 @default.
- W4313389063 cites W3137708143 @default.
- W4313389063 cites W3144992645 @default.
- W4313389063 cites W3158218790 @default.
- W4313389063 cites W3176300946 @default.
- W4313389063 cites W3177808128 @default.
- W4313389063 cites W3193564204 @default.
- W4313389063 cites W3198094729 @default.
- W4313389063 cites W3202417786 @default.
- W4313389063 cites W3206879044 @default.
- W4313389063 cites W3215546577 @default.
- W4313389063 cites W4200407362 @default.
- W4313389063 cites W4211147776 @default.
- W4313389063 cites W4223484773 @default.
- W4313389063 cites W4247506353 @default.
- W4313389063 cites W4281562408 @default.
- W4313389063 cites W4281754067 @default.
- W4313389063 cites W4282592293 @default.
- W4313389063 cites W4284879216 @default.
- W4313389063 cites W4284888782 @default.